

**Amendments to the Claims:**

Please amend the claims as follows:

- 1-16. (canceled)
17. (currently amended) A method for screening compounds for receptor tyrosine kinase (RTK) agonists or RTK antagonists comprising:
- (a) crystallizing a modified RTK polypeptide, said modified RTK polypeptide having kinase activity and comprising RTK kinase domain  $\alpha$  helix D linked to RTK kinase domain  $\alpha$  helix E by a truncated RTK kinase insert domain (KID), wherein the modified RTK polypeptide is vascular endothelial growth factor receptor-2 (VEGFR-2);
  - (b) obtaining crystallography coordinates for said modified RTK polypeptide;
  - (c) applying said crystallography coordinates for said modified RTK polypeptide in order to generate a model of said modified RTK polypeptide suitable for use in designing molecules compounds that will act as agonists or antagonists to said modified RTK polypeptide; and
  - (d) applying an iterative process whereby various molecular structures are applied to said model to identify agonists or antagonists to said modified RTK polypeptide.
18. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 50 residues from the KID.
19. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 60 residues from the KID.
20. (previously presented) The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of the highly charged residues from the KID.
21. (previously presented) The method of claim 17 wherein said truncated kinase insert domain linking said  $\alpha$  helix D to said  $\alpha$  helix E is of a sufficient length so as to allow said helices to maintain appropriate conformation associated with competent kinase structure.
- 22.-25. (canceled)
26. (previously presented) The method of claim 17 wherein said modified RTK polypeptide comprises VEGFR2 $\Delta$ 50 polypeptide of SEQ ID NO: 5.

27. (new) A method for screening compounds for receptor tyrosine kinase (RTK) agonists or RTK antagonists comprising:
- (a) crystallizing a modified RTK polypeptide, said modified RTK polypeptide having kinase activity and comprising RTK kinase domain  $\alpha$  helix D linked to RTK kinase domain  $\alpha$  helix E by a truncated RTK kinase insert domain (KID), wherein the modified RTK polypeptide comprises the VEGFR2 $\Delta$ 50 polypeptide of SEQ ID NO: 5;
  - (b) obtaining crystallography coordinates for said modified RTK polypeptide;
  - (c) applying said crystallography coordinates for said modified RTK polypeptide in order to generate a model of said modified RTK polypeptide suitable for use in designing molecules compounds that will act as agonists or antagonists to said modified RTK polypeptide; and
  - (d) applying an iterative process whereby various molecular structures are applied to said model to identify agonists or antagonists to said modified RTK polypeptide.